Zoetis Inc. (NYSE:
ZTS) is one of the
best drug stocks to buy right now. Zoetis Inc. (NYSE:ZTS) announced on September 12 the adoption of a positive opinion by the Committee for Veterinary Medicinal Products (CVMP) of the European Medicines Agency (EMA) regarding recommending the granting of marketing authorization for Portela (relfovetmab).
Portela is a new monoclonal antibody (mAb) therapy intended to alleviate pain associated with osteoarthritis (OA) in cats. Zoetis Inc. (NYSE:ZTS) reported that if approved, Portela would be the first long-acting anti-nerve growth factor (NGF) mAb therapy for cats.
It is designed to offer “three months of osteoarthritis (OA) pain relief with a single injection,” as it targets NGF, a key mediator of OA pain.
Management further reported that the CVMP recommended the grant of marketing authorization based on a positive benefit-risk balance of the safety and efficacy data submitted.
Zoetis Inc. (NYSE:ZTS) is a global animal health company that focuses on the discovery, development, manufacture, and commercialization of vaccines, medicines, biodevices, genetic tests, diagnostic products, and precision animal health.
Its operations are divided into the United States and International segments. Each segment boasts a diversified product portfolio, including vaccines, parasiticides, pain and sedation, animal health diagnostics, and more.
The company markets its products in around 45 countries across the globe and specializes in products across eight core species: companion animals (dogs, cats, and horses), cattle, swine, livestock (sheep and fish), and poultry.
While we acknowledge the potential of ZTS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the
best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at
Insider Monkey.
